Your browser doesn't support javascript.
loading
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.
Milojkovic, Dragana; Cross, Nicholas C P; Ali, Sahra; Byrne, Jenny; Campbell, Gavin; Dignan, Fiona L; Drummond, Mark; Huntly, Brian; Marshall, Scott; McMullin, Mary Frances; Neelakantan, Pratap; Raghavan, Manoj; Sivakumaran, Muttuswamy; Tighe, Jane; Wandroo, Farooq; Willis, Fenella; Glen, Fiona; Fildes, Louise; Collington, Sarah J; Ryan, Jacqueline; Clark, Richard E; Mead, Adam J.
Afiliación
  • Milojkovic D; Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Cross NCP; University of Southampton, Southampton, UK.
  • Ali S; Castle Hill Hospital, Hull and East Yorkshire Hospitals NHS Trust, Cottingham, UK.
  • Byrne J; Nottingham City Hospital, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Campbell G; Colchester Hospital University NHS Foundation Trust, Colchester, UK.
  • Dignan FL; Manchester Royal Infirmary, Manchester University Hospitals Foundation Trust, Manchester, UK.
  • Drummond M; Beatson Cancer Centre, Glasgow, UK.
  • Huntly B; Addenbrookes, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Marshall S; Sunderland Royal Hospital, City Hospitals Sunderland NHS Foundation Trust, Sunderland, UK.
  • McMullin MF; Belfast City Hospital, Belfast Health and Social Care Trust, Belfast, UK.
  • Neelakantan P; Royal Berkshire, Royal Berkshire NHS Foundation Trust, Belfast, UK.
  • Raghavan M; Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Sivakumaran M; Peterborough City Hospital, Northwest Anglia NHS Foundation Trust, Peterborough, UK.
  • Tighe J; Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK.
  • Wandroo F; Sandwells District General Hospital, Sandwells and West Birmingham Hospitals NHS Trust, West Bromwich, UK.
  • Willis F; St George's University Hospitals NHS Foundation Trust, London, UK.
  • Glen F; OPEN VIE, Marlow, UK.
  • Fildes L; Novartis Pharmaceuticals UK Limited, London, UK.
  • Collington SJ; Novartis Pharmaceuticals UK Limited, London, UK.
  • Ryan J; Novartis Pharmaceuticals UK Limited, London, UK.
  • Clark RE; Royal Liverpool University Hospital, Liverpool, UK.
  • Mead AJ; NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK.
Br J Haematol ; 192(1): 62-74, 2021 01.
Article en En | MEDLINE | ID: mdl-32449159
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Inhibidores de Proteínas Quinasas / Mesilato de Imatinib Tipo de estudio: Guideline / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Br J Haematol Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Inhibidores de Proteínas Quinasas / Mesilato de Imatinib Tipo de estudio: Guideline / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Br J Haematol Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido